MannKind Corp. Hits New 52-Week Low at $2.94 Amid Declining Stock Performance

MannKind Corp., a small-cap player in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week low of USD 2.94 as of February 26, 2026. This marks a significant decline, with the stock's performance over the past year showing a decrease of 27.84%, contrasting sharply with the S&P 500's gain of 12.95% during the same period. The company's market capitalization stands at USD 1,701 million, and it currently has a price-to-earnings (P/E) ratio of 38.00. However, MannKind Corp. faces challenges reflected in its financial metrics, including a negative return on equity of -106.42% and a debt-to-equity ratio of 3.09, indicating a high level of debt relative to equity. The stock's price-to-book ratio is notably low at -38.18, further highlighting its financial difficulties. Despite a reported growth in operating profit at an annual rate of 36.97% over the last five years, the company's ability to manage its debt remains a concern, as evidenced by a poor EBIT to interest ratio of -1.07. Overall, MannKind Corp.'s recent performance underscores a challenging landscape for the company within its industry.